NEW YORK, NY--(Marketwired - Jul 15, 2013) - The following is and investment opinion on Inovio Pharmaceuticals (NYSE MKT: INO), Arch Therapeutics (OTCQB: ARTH), Merck (NYSE: MRK) and OncoSec medical (OTCQB: ONCS).

Dr. Avtar Dhillon has been announced as the Chairman of the Board of Directors for Arch Therapeutics (OTCQB: ARTH) after leading Inovio Pharmaceuticals (NYSE MKT: INO) as CEO for over 7 years. Previously, Dr. Dhillon was the President and Chief Executive Officer of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation) from October 2001 to June 2009. Under his reign, Inovio enjoyed tremendous success corporately and publicly where in 2004, Inovio Pharmeceuticals reached over $7.50 per share.

Dr. Dhillon has a multi-faceted background in the medical field, as both an executive on the board of different healthcare companies as well as being involved with one of North America's leading healthcare venture capital firms, MDS Capital, now Lumira Capital Corp.

Dr. Dhillon helped lead the turnaround of Inovio through restructuring, the acquisition of technology and a merger with VGX Pharmaceuticals to help develop a vertically integrated DNA vaccine development company. He also spearheaded multiple financings and closed several licensing deals with the likes of Wyeth (now Pfizer) and Merck (NYSE: MRK). Dr. Avtar Dhillon is now helping to lead Arch Therapeutics along the path to success.

Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch's flagship development stage product candidate known as AC5™ is being designed to elegantly achieve hemostasis in minimally invasive and open surgical procedures. For more information about Arch Therapeutics please visit www.archtherapeutics.com

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO Circuit twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.